NPI 1790722049: Open Payments
NPI 1790722049. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$425 in 19 payments from 9 companies in 2025. Trend: 2023 $1,101 · 2024 $1,540 · 2025 $425
Food & beverage: $425
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $113 |
| Novo Nordisk Inc | 3 | $79 |
| ABBVIE INC. | 2 | $47 |
| Amgen Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Abbott Laboratories | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
Products named: JARDIANCE, MOUNJARO, OTEZLA, NEXLETOL, FREESTYLE LIBRE 3, XIFAXAN, Ozempic, VRAYLAR.
